118 related articles for article (PubMed ID: 18563832)
1. Comparative preclinical drug metabolism and pharmacokinetic evaluation of novel 4-aminoquinoline anti-malarials.
Davis CB; Bambal R; Moorthy GS; Hugger E; Xiang H; Park BK; Shone AE; O'Neill PM; Ward SA
J Pharm Sci; 2009 Jan; 98(1):362-77. PubMed ID: 18563832
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
3. Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.
O'Neill PM; Park BK; Shone AE; Maggs JL; Roberts P; Stocks PA; Biagini GA; Bray PG; Gibbons P; Berry N; Winstanley PA; Mukhtar A; Bonar-Law R; Hindley S; Bambal RB; Davis CB; Bates M; Hart TK; Gresham SL; Lawrence RM; Brigandi RA; Gomez-delas-Heras FM; Gargallo DV; Ward SA
J Med Chem; 2009 Mar; 52(5):1408-15. PubMed ID: 19222165
[TBL] [Abstract][Full Text] [Related]
4. Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials.
O'Neill PM; Mukhtar A; Stocks PA; Randle LE; Hindley S; Ward SA; Storr RC; Bickley JF; O'Neil IA; Maggs JL; Hughes RH; Winstanley PA; Bray PG; Park BK
J Med Chem; 2003 Nov; 46(23):4933-45. PubMed ID: 14584944
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
O'Neill PM; Shone AE; Stanford D; Nixon G; Asadollahy E; Park BK; Maggs JL; Roberts P; Stocks PA; Biagini G; Bray PG; Davies J; Berry N; Hall C; Rimmer K; Winstanley PA; Hindley S; Bambal RB; Davis CB; Bates M; Gresham SL; Brigandi RA; Gomez-de-Las-Heras FM; Gargallo DV; Parapini S; Vivas L; Lander H; Taramelli D; Ward SA
J Med Chem; 2009 Apr; 52(7):1828-44. PubMed ID: 19284751
[TBL] [Abstract][Full Text] [Related]
6. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.
Jayaraman R; Pilla Reddy V; Pasha MK; Wang H; Sangthongpitag K; Yeo P; Hu CY; Wu X; Xin L; Goh E; New LS; Ethirajulu K
Drug Metab Dispos; 2011 Dec; 39(12):2219-32. PubMed ID: 21873472
[TBL] [Abstract][Full Text] [Related]
7. Preclinical drug metabolism and pharmacokinetic evaluation of GW844520, a novel anti-malarial mitochondrial electron transport inhibitor.
Xiang H; McSurdy-Freed J; Moorthy GS; Hugger E; Bambal R; Han C; Ferrer S; Gargallo D; Davis CB
J Pharm Sci; 2006 Dec; 95(12):2657-72. PubMed ID: 16892205
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey.
Ward KW; Azzarano LM
J Pharmacol Exp Ther; 2004 Aug; 310(2):703-9. PubMed ID: 15056727
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
11. Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers. Species comparison and allometric scaling.
Feng MR; Loo J; Wright J
Drug Metab Dispos; 1998 Oct; 26(10):982-8. PubMed ID: 9763403
[TBL] [Abstract][Full Text] [Related]
12. Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
Vuong C; Xie LH; Potter BM; Zhang J; Zhang P; Duan D; Nolan CK; Sciotti RJ; Zottig VE; Nanayakkara NP; Tekwani BL; Walker LA; Smith PL; Paris RM; Read LT; Li Q; Pybus BS; Sousa JC; Reichard GA; Smith B; Marcsisin SR
Antimicrob Agents Chemother; 2015 Jul; 59(7):3864-9. PubMed ID: 25870069
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques.
Ramanathan-Girish S; Catz P; Creek MR; Wu B; Thomas D; Krogstad DJ; De D; Mirsalis JC; Green CE
Int J Toxicol; 2004; 23(3):179-89. PubMed ID: 15204721
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance.
Ward KW; Smith BR
Drug Metab Dispos; 2004 Jun; 32(6):603-11. PubMed ID: 15155551
[TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey.
Adams WJ; McGovren JP; Dalm EA; Brewer JE; Hosley JD
Cancer Res; 1989 Nov; 49(22):6328-36. PubMed ID: 2529962
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist.
Vachharajani NN; Yeleswaram K; Boulton DW
J Pharm Sci; 2003 Apr; 92(4):760-72. PubMed ID: 12661062
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
[TBL] [Abstract][Full Text] [Related]
19. Effects of formulation and route of administration on the systemic availability of Ex-RAD®, a new radioprotectant, in preclinical species.
Chun AW; Freshwater RE; Taft DR; Gillum AM; Maniar M
Biopharm Drug Dispos; 2011 Mar; 32(2):99-111. PubMed ID: 21341279
[TBL] [Abstract][Full Text] [Related]
20. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
Wong H; Chen JZ; Chou B; Halladay JS; Kenny JR; La H; Marsters JC; Plise E; Rudewicz PJ; Robarge K; Shin Y; Wong S; Zhang C; Khojasteh SC
Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
